Self Reported Deviations From Opioid Analgesic Prescription
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00907192|
Recruitment Status : Completed
First Posted : May 22, 2009
Last Update Posted : June 18, 2013
- To determine the frequency of self-reported over and under use of opioid analgesics in patients with advanced cancer. Patients with advanced cancer are those patients who have been described to have either one of the following: recurrent disease, those that have failed multiple chemotherapies (more than second line therapy), locally advanced disease, and metastatic disease.
- To determine the association between patients' knowledge, attitudes and beliefs about opioids, and frequency of deviation in opioid use with patients' demographic information.
- To determine association between alcohol abuse/chemical coping and self-reported deviations in opioid use.
- To determine the association between the use of opioids and patient-related barriers to opioid use.
|Condition or disease||Intervention/treatment|
|Advanced Cancers||Behavioral: Personal Interview Behavioral: Questionnaire|
Before you start the study, the research nurse will check your medical record to see if you are eligible to take part in this study. Information will be recorded about your demographics (such as age, marital status, ethnicity, education level, and gender), medical history (such as the type of cancer and level of pain), and prescriptions (such as the name of any opioid drugs, doses, and schedule).
If you are found to be eligible to take part in this study, you will be interviewed by the study staff before a regular visit with your doctor. You will be asked some questions about your use of pain drugs and other knowledge and/or attitudes that you may have about them. You may also be asked for general information (such as your age, marital status, or educational level) if it was not available in your chart and medical record.
After the interview, you will complete 5 short questionnaires about your use of pain drugs, your attitudes about the pain drugs and their use, and concerns that you may have about your use of these pain drugs.
It will take about 5-10 minutes for the interview and another 10-15 minutes to complete all the questionnaires.
Your interview and questionnaire responses will not be shared with your regular doctor unless the study staff feels that you maybe be at harm. If you feel you need a doctor's opinion about anything that is asked in the interview and/or questionnaires, please contact your doctor.
Your interview and questionnaire responses will only be used for this research study and will not be shared with your family members.
Length of Study:
After completing the interview and questionnaires, your participation in this study will be over.
This is an investigational study. Up to 200 patients will take part in this study. All will be enrolled at M. D. Anderson.
|Study Type :||Observational|
|Actual Enrollment :||201 participants|
|Official Title:||The Influence of Patients' Knowledge, Attitudes and Beliefs on Self Reported Deviations From Opioid Analgesic Prescription: an Exploratory Survey|
|Study Start Date :||May 2009|
|Actual Primary Completion Date :||June 2012|
|Actual Study Completion Date :||June 2012|
Personal Interview and Questionnaire of Advanced cancer patients, taking narcotic pain drugs (opioids).
Behavioral: Personal Interview
Interview questions about use of pain drugs and other knowledge and/or attitudes about them. Take about 5-10 minutes to complete.Behavioral: Questionnaire
5 short questionnaires about use of pain drugs, attitudes about the pain drugs and their use, and concerns about use of these pain drugs. Take about 10-15 minutes to complete.
Other Name: Survey
- Number of Persons with Advanced Cancer who Self-report Opioid Analgesics Over/Under [ Time Frame: 2 Years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00907192
|United States, Texas|
|UT MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Study Chair:||Eduardo Bruera, MD||UT MD Anderson Cancer Center|